^
Association details:
| Biomarker: | ALK wild-type |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Results from the IMpower132 China cohort: Atezolizumab plus platinum-based chemotherapy in advanced non-small cell lung cancer
Published date:
09/02/2022
Excerpt:
Treatment-naive Chinese patients with non-squamous stage IV EGFR/ALK mutation-negative NSCLC were randomized 1:1 to receive 4 or 6 cycles of APP or PP….Among Chinese patients in IMpower132, PFS benefit was seen with APP versus PP.
Secondary therapy:
carboplatin + pemetrexed; cisplatin + pemetrexed
DOI:
https://doi.org/10.1002/cam4.5144
Trial ID:
